The contract research organization consolidation trend continues with Worldwide Clinical Trials striking a deal for Catalyst Clinical Research, which has particular expertise in oncology. Worldwide is a portfolio company of Kohlberg, a private equity firm.
IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company's Q2 Solutions unit. The deal follows IQVIA's April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
A recruiter in the industry said trial-monitoring staff report having their hours cut, while CRAs are grounded, and others have reported being laid off on social media. Several drugmakers have wound down clinical trial operations as the pandemic has overwhelmed a growing number of hospitals.
In a survey of 170 sites, Continuum Clinical found that around one-third of sites anticipate impacts on their ability to recruit and retain participants. The FDA guidance listed considerations patient protection and conduct of trials during the pandemic.
The guidance concerned strategies for developing precision medicines and more efficient clinical trial oversight. But the outgoing commissioner criticized drugmakers and CROs' reluctance to change their ways.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The Veeva Systems survey found that clinical trial management systems pose issues for trials. Physicians interviewed for a story last month voiced similar concerns.
CROs and sponsors alike may be to blame for poor clinical trial coordination, but investigators complain about shoddy tech, poor communication and busywork.
As clinical trial compliance and disclosure remain in the spotlight and more and more countries continue to establish regulations, it is more important now than ever for sponsors to adopt a Global Transparency Policy.
If you had to do an infographic following the trajectory of clinical trial payments between the pharmaceutical companies that sponsor global clinical trials and the principal investigators who run them, it would resemble something like tangled spaghetti. Why? Each principal investigator contract is separately negotiated and depends on the experiment. They are also located at […]
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.